How does NTRK fusion affect Colorectal Cancer treatment options

NTRK Fusions in Colorectal Cancer: What You Need to Know

What Is an NTRK Fusion?

An NTRK fusion occurs when genes called NTRK (neurotrophic tyrosine receptor kinase) become abnormally joined to other genes in your cancer cells. This creates a faulty protein that signals cancer cells to grow uncontrollably. Think of it like a broken "on switch" that gets stuck in the "grow" position.

How Common Is This in Colorectal Cancer?

NTRK fusions are extremely rare in colorectal cancer (CRC). According to the NCCN Guidelines for Colon Cancer, only about 0.2% to 1% of colorectal cancers carry NTRK fusions—meaning it's found in roughly 1 out of every 100-500 patients.

Importantly, NTRK fusions in CRC are almost always found in tumors that are:

• Wild-type for KRAS, NRAS, and BRAF (meaning these other cancer-driving genes are normal)
• Often MMR-deficient (about 77% of NTRK-positive CRCs have defective mismatch repair)

How Does This Change Treatment?

The Clinical Reasoning

When doctors discover an NTRK fusion, it opens up a targeted therapy approach. Instead of using standard chemotherapy that affects all rapidly dividing cells, targeted therapies work like a "smart bomb"—they specifically attack the faulty protein created by the NTRK fusion.

Treatment Options That Exist

According to NCCN Guidelines, three FDA-approved NTRK inhibitors (drugs that block the faulty protein) are available:

1. Larotrectinib - Shows a 79% overall response rate with a median progression-free survival of 28.3 months
2. Entrectinib - Demonstrates 61% response rates with median duration of response around 20 months
3. Repotrectinib - Newer option with 58% response rate in treatment-naive patients

These drugs are typically used in the second-line or subsequent therapy setting (after initial treatment has progressed).

Important Testing Considerations

NTRK fusion detection matters because:

• IHC (immunohistochemistry) testing alone can be misleading — about 1 in 5 tumors that test positive by IHC are actually false positives
• RNA-based NGS (next-generation sequencing) is the gold standard for confirming NTRK fusions, as it directly detects the functional fusion
• DNA-based NGS shows 81% sensitivity and 99.9% specificity compared to RNA testing

Questions to Ask Your Oncologist

If you have colorectal cancer and are considering molecular testing:

1. "Has my tumor been tested for NTRK fusions?" If not, ask whether testing is appropriate for your stage and situation.

2. "If I have an NTRK fusion, which NTRK inhibitor would you recommend and why?" (larotrectinib, entrectinib, or repotrectinib)

3. "What response rates and side effects should I expect with NTRK-targeted therapy?"

4. "How will we monitor whether the NTRK inhibitor is working?" (imaging, tumor markers, etc.)

5. "Are there clinical trials available for NTRK-positive CRC?"

Key Takeaway

While NTRK fusions are uncommon in colorectal cancer, finding one is actually good news because it means your tumor has a specific vulnerability that can be targeted with precision medicines. These targeted therapies often work better and have different side effect profiles than standard chemotherapy.

---

Sources:

• NCCN Guidelines for Colon Cancer (Version 5.2025) - NTRK Fusions section
• NCCN Guidelines for Rectal Cancer (Version 4.2025) - Molecular testing recommendations

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.